World Health Organization site
Skip Navigation Links

Please fill this short user satisfaction survey


Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 30 June 2019
Main ID:  EUCTR2004-000074-31-BE
Date of registration: 07/07/2004
Prospective Registration: Yes
Primary sponsor: Merck Sharp & Dohme BV
Public title: A Placebo-Controlled, Parallel-Group, Double-Blind, 12-Week Study to Assess the Clinical Efficacy, Safety, and Tolerability of L-000124467 in Rheumatoid Arthritis Patients - Efficacy, Tolerability and Safety Study in Rheumatoid Arthritis
Scientific title: A Placebo-Controlled, Parallel-Group, Double-Blind, 12-Week Study to Assess the Clinical Efficacy, Safety, and Tolerability of L-000124467 in Rheumatoid Arthritis Patients - Efficacy, Tolerability and Safety Study in Rheumatoid Arthritis
Date of first enrolment: 15/03/2005
Target sample size: 150
Recruitment status: Not Recruiting
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000074-31
Study type:  Interventional clinical trial of medicinal product
Study design: 
Controlled: yes
Randomised: yes
Open: no
Single blind: no
Double blind: yes
Parallel group: yes
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: yes
Other: yes
Other specify the comparator: paracetamol (acetaminophen) tablets - Rescue Medication)
 
Phase:  Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no
Countries of recruitment
Belgium Sweden
Contacts
Name:    
Address: 
Telephone:
Email:
Affiliation: 
Name:    
Address: 
Telephone:
Email:
Affiliation: 
Key inclusion & exclusion criteria
Inclusion criteria:
Patients’ diagnosis of rheumatoid disease must meet or have met 1987 ARA revised diagnostic criteria. Patients must have active RA with a minimum level of disease activity including at least 10 swollen joints and 10 tender or painful joints, a Patient Global Assessment of Disease Activity of >40 mm (on a 100-mm Visual Analog Scale [VAS]), an Investigator Global Assessment of Disease Activity of fair, poor, or very poor (on a 5-point Likert scale), and 1 of the following: an ESR greater than or equal to 26, a CRP of at least 2.0 mg/dL (SI units: ³20.0 mg/L) or morning stiffness that lasts at least 45 minutes at Visits 1.0 and Visit 2.0.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion criteria:
Patients will undergo tuberculin purified protein derivative (PPD) testing prior to randomization in to the study. Patients with evidence of on-going or previous tuberculosis (TB) infection will not be eligible for participation in the study.


Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
rheumatoid arthritis
MedDRA version: 7.0 Level: LLT Classification code 10039073
Intervention(s)

Product Name: 1,5-anhydro-2,3-dideoxy-3-[[(1R,3S)-3-[[7,8-dihydro-3- (trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]c
Product Code: L-000124467 (freebase); L-000124467-009J (succinat
Pharmaceutical Form: Tablet
INN or Proposed INN: not available
Other descriptive name: L-000124467
Concentration unit: mg milligram(s)
Concentration number: 0.2-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use

Product Name: 1,5-anhydro-2,3-dideoxy-3-[[(1R,3S)-3-[[7,8-dihydro-3- (trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]c
Product Code: L-000124467 (freebase); L-000124467-009J (succinat
Pharmaceutical Form: Tablet
INN or Proposed INN: not available
Other descriptive name: L-000124467
Concentration unit: mg milligram(s)
Concentration number: 1.0-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use

Product Name: 1,5-anhydro-2,3-dideoxy-3-[[(1R,3S)-3-[[7,8-dihydro-3- (trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]c
Product Code: L-000124467 (freebase); L-000124467-009J (succinat
Pharmaceutical Form: Tablet
INN or Proposed INN: not available
Other descriptive name: L-000124467
Concentration unit: mg milligram(s)
Concentration number: 5.0-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use

Trade Name: paracetamol (acetaminophen)
Product Name: paracetamol (acetaminophen)
Pharmaceutical Form: Tablet
CAS Number: 103-90-2
Concentration unit: mg milligram(s)
Primary Outcome(s)
Primary end point(s): Swollen joint count
Main Objective: To demonstrate the clinical efficacy of L-000124467 in the treatment of rheumatoid arthritis.
Secondary Objective: To demonstrate the safety and tolerability of L-000124467 0.4 and 10.0 mg once daily for 12 weeks in RA patients.
Secondary Outcome(s)
Secondary ID(s)
2004-000074-31-SE
0812-008
Source(s) of Monetary Support
Secondary Sponsor(s)
Ethics review
Status: Approved
Approval date:
Contact:
Results
Results available: Yes
Date Posted: 13/10/2016
Date Completed: 09/05/2005
URL: https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000074-31/results
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history Please fill this short user satisfaction survey